The company is recording a significant $127 million pre-tax charge for acquired in-process R&D from collaboration and licensing deals. This expense directly compresses quarterly profitability and may increase internal focus on cost management and operational efficiency to offset the earnings impact.
Filing excerpt
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $127 million on a pre-tax basis.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kmarginPressureGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/2a40be62-dc8c-4001-8368-90bf36930b0e returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "2a40be62-dc8c-4001-8368-90bf36930b0e",
"signal_type": "sec-8k",
"signal_subtype": "marginPressure",
"detected_at": "2026-07-07T07:07:04.456+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "The company is recording a significant $127 million pre-tax charge for acquired in-process R&D from collaboration and licensing deals. This expense directly compresses quarterly profitability and may increase internal focus on cost management and operational efficiency to offset the earnings impact.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development (IPR&D) pre-tax charge",
"dollar_millions": 127
},
"summary": "Regeneron to take a $127M charge in Q2 2026, negatively impacting earnings per share by ~$1.00.",
"excerpts": "Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $127 million on a pre-tax basis.",
"relevance": 0.8,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm",
"filing_date": "2026-07-06",
"filing_year": 2026,
"sales_relevance": "Efficiency tools needed",
"signal_category": "financial"
}
}
curl https://signals.autobound.ai/v1/signals/2a40be62-dc8c-4001-8368-90bf36930b0e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.